Cipher Pharmaceuticals (TSE:CPH) Shares Pass Above 50-Day Moving Average – Should You Sell?

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR)’s share price crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of C$14.92 and traded as high as C$15.84. Cipher Pharmaceuticals shares last traded at C$15.46, with a volume of 58,123 shares trading hands.

Wall Street Analysts Forecast Growth

CPH has been the topic of a number of research analyst reports. Stifel Canada upgraded Cipher Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, August 12th. Stifel Nicolaus increased their target price on shares of Cipher Pharmaceuticals from C$16.00 to C$17.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. Finally, Leede Financial downgraded shares of Cipher Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 13th.

Cipher Pharmaceuticals Stock Up 1.9 %

The company has a quick ratio of 2.67, a current ratio of 11.18 and a debt-to-equity ratio of 0.33. The stock has a 50-day simple moving average of C$15.19 and a 200-day simple moving average of C$10.94. The firm has a market capitalization of C$403.04 million, a PE ratio of 12.91 and a beta of 1.25.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last released its quarterly earnings data on Thursday, August 8th. The company reported C$0.16 earnings per share for the quarter, beating analysts’ consensus estimates of C$0.15 by C$0.01. Cipher Pharmaceuticals had a net margin of 102.01% and a return on equity of 28.43%. The business had revenue of C$7.26 million during the quarter, compared to analyst estimates of C$7.52 million. Analysts forecast that Cipher Pharmaceuticals Inc. will post 1.5059761 EPS for the current year.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.